BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y. The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. Pharmacol Ther 2021;218:107677. [PMID: 32898548 DOI: 10.1016/j.pharmthera.2020.107677] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Zhang C, Wu E, Han L, Deng X, Shi Z. UPLC-Q-TOF/MS-Based Metabolomics Approach Reveals Osthole Intervention in Breast Cancer 4T1 Cells. Int J Mol Sci 2023;24. [PMID: 36674685 DOI: 10.3390/ijms24021168] [Reference Citation Analysis]
2 Wang W, Zhu T, Chen H, Yao Y. The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer. Clin Transl Oncol 2022. [PMID: 36586066 DOI: 10.1007/s12094-022-03062-9] [Reference Citation Analysis]
3 Ebrahimi N, Fardi E, Ghaderi H, Palizdar S, Khorram R, Vafadar R, Mobarak H, Ahmadi A, Hamblin MR, Aref AR. Receptor Tyrosine Kinase Inhibitors in Cancer Immunotherapy.. [DOI: 10.21203/rs.3.rs-2251865/v1] [Reference Citation Analysis]
4 Liu X, Yang B, Huang X, Yan W, Hu G. Identifying Lymph Node Metastasis-related Factors in Breast Cancer using Differential Modular and Mutational Structural Analysis.. [DOI: 10.1101/2022.09.06.506724] [Reference Citation Analysis]
5 Sajjadi E, Venetis K, Ivanova M, Fusco N. Improving HER2 testing reproducibility in HER2-low breast cancer. Cancer Drug Resist 2022;5:882-8. [PMID: 36627898 DOI: 10.20517/cdr.2022.29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu Q, Mei Y, Zhang W, Zhang Y. The Combination Therapy in Breast Cancer Treatment. HSET 2022;8:591-596. [DOI: 10.54097/hset.v8i.1219] [Reference Citation Analysis]
7 Awah CU, Glemaud Y, Levine F, Yang K, Ansary A, Dong F, Ash L, Zhang J, Weiser D, Ogunwobi OO. Destabilized 3’UTR ARE therapeutically degrades ERBB2 in drug-resistant ERBB2+ cancer models.. [DOI: 10.1101/2022.08.14.503914] [Reference Citation Analysis]
8 Kusumastuti R, Kumagai Y, Ishihara S, Enomoto A, Murakami T, Yasuda M, Haga H. Mammaglobin 1 mediates progression of trastuzumab-resistant breast cancer cells through regulation of cyclins and NF-κB. FEBS Open Bio 2022;12:1797-813. [PMID: 35945910 DOI: 10.1002/2211-5463.13468] [Reference Citation Analysis]
9 Rocca A, Kholodenko BN. Can Systems Biology Advance Clinical Precision Oncology? Cancers (Basel) 2021;13:6312. [PMID: 34944932 DOI: 10.3390/cancers13246312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang X, Leng J, Zhou Y, Mao F, Lin Y, Shen S, Sun Q. Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis. Front Oncol 2021;11:731210. [PMID: 34490125 DOI: 10.3389/fonc.2021.731210] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, Willingham S, Ho PY, Rosental B, Tal MC, Raveh T, Volkmer JP, Pegram MD, Weissman IL. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A 2021;118:e2026849118. [PMID: 34257155 DOI: 10.1073/pnas.2026849118] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]